With long-term data in hand, Vivek Ramaswamy's Dermavant team dashes to the goal line with topical psoriasis contender
Months after touting positive data from two pivotal Phase IIIs, Vivek Ramaswamy’s Dermavant team is back with long-term data to back its psoriasis candidate tapinarof — and it’s headed for the FDA.
About 91% of the 1,025 patients in Dermavant’s PSOARING 1 and 2 Phase III studies opted to roll into PSOARING 3, a long-term safety analysis, CEO Todd Zavodnick said. But the study ended up being much more than a safety trial.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.